Article Text

Download PDFPDF
Prognostic RNAs in oesophageal squamous cell carcinoma: small is beautiful
  1. Patrick Tan1,2,
  2. Russell Petty3
  1. 1Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore
  2. 2Biomedical Research Council, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
  3. 3Division of Cancer Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
  1. Correspondence to Dr Patrick Tan, Cancer and Stem Cell Biology Program, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; gmstanp{at} and Dr Russel Petty, Division of Cancer Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; r.petty{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Oesophageal cancer is a deadly malignancy and is highly heterogeneous at the histological, geographical and molecular levels. It is broadly divided into adenocarcinomas and oesophageal squamous cell carcinomas (OSCCs). OSCCs are particularly prevalent in Asia and Africa where the disease has been linked to tobacco smoking, alcohol consumption and population-specific genetic risk variants.1 Clinically, oesophagectomy is the standard of care for curative therapy, usually proceeded by neoadjuvant chemotherapy/concurrent chemoradiotherapy, or in some cases definitive chemoradiotherapy without surgery. Unfortunately, the majority of patients with OSCC will relapse, and many either present too late or are too frail for curative treatment, resulting in an overall 5-year survival rate of 20%. Recent genomic studies have revealed a plethora of genetic alterations in OSCC, including mutations in TP53, PIK3CA and chromatin modifier genes.2–4 Robust approaches are thus needed for accurately subtyping patients with OSCC, to tailor existing therapies and to identify subtype-specific driver alterations that may highlight opportunities for novel interventions. Interestingly, several genomic alterations in OSCC are also observed in squamous carcinomas from other body sites, including the lung.

Previous studies applying molecular profiling to predict prognosis of patients with OSCC have suffered from limitations challenging their widespread clinical applicability.5 ,6 These include the lack of demonstrated validation in multiple independent cohorts from different patient populations, and a requirement to measure large numbers of genes to achieve accurate classification. Technical challenges also exist, particularly in …

View Full Text


  • Contributors PT and RP participated in writing this commentary.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles

  • Oesophagus
    Hee-Jin Jang Hyun-Sung Lee Bryan M Burt Geon Kook Lee Kyong-Ah Yoon Yun-Yong Park Bo Hwa Sohn Sang Bae Kim Moon Soo Kim Jong Mog Lee Jungnam Joo Sang Cheol Kim Ju Sik Yun Kook Joo Na Yoon-La Choi Jong-Lyul Park Seon-Young Kim Yong Sun Lee Leng Han Han Liang Duncan Mak Jared K Burks Jae Ill Zo David J Sugarbaker Young Mog Shim Ju-Seog Lee